Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stem cell therapy in non-ischemic non-treatable dilated cardiomyopathy
2018-002538-19Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Oct 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CSCC_ASC in dilated cardiomyopathy (DCM), sponsored by Rigshospitalet. Primary endpoint: Left ventricle end-systolic volume. Started Oct 2018; status: completed.
02
Drugs
CSCC_ASC
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on 2018-002538-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002538-19.